英特格拉生命科學 IART 深 滬
等待開盤 04-01 09:30:00 美东时间
9.42
+0.300
+3.29%
華盛通- 最 高9.455
- 今 開9.27
- 成交量 79.54万股
- 最 低 8.87
- 昨 收 9.12
- 總市值 7.34亿
- 52周最高 17.54
- 市盈率 靜 --
- 換手率 1.02%
- 52周最低 8.70
- 委 比 46.99%
- 總股本 7793.72万
- 歷史最高 77.40
- 量 比 1.08
- 振 幅 6.41%
- 歷史最低 8.36
- 每 手 1
- 風險率 2.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多新浪财经ESG：英特格拉生命科学 MSCI（明晟）ESG评级调降至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:23
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility
Small-cap outperformance has narrowed over the last couple of weeks as investor caution increased, with volatility and geopolitical risk weighing on risk appetite and narrowing the performance gap vs....
03-19 01:25
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Integra Lifesciences Sees FY2026 Adj EPS $2.30-$2.40 vs $2.35 Est; Sees Sales $1.662B-$1.702B vs $1.675B Est
Integra Lifesciences (NASDAQ:IART) is looking for FY2026 Adj EPS of $2.30-$2.40 vs $2.35 analyst estimate. sees sales of $1.662 billion-$1.702 billion vs $1.675 billion analyst estimate.
02-26 19:04
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Kyverna Therapeutics announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D., to its Board of Directors. Mr. Emany brings extensive financial and strategic leadership experience, while Dr. Miller adds expertise in clinical development and product approval. Their加入 strengthens the company as it advances toward commercialization and long-term success in autoimmune CAR T therapies.
02-24 13:00
Integra LifeSciences Appoints Elavia, Hutchinson, and DiPietro to Executive Roles
Integra LifeSciences Appoints Elavia, Hutchinson, and DiPietro to Executive Roles Integra LifeSciences Holdings Corporation has announced key executive leadership appointments, including Teshtar Elavia as chief technology officer, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chie
02-17 21:30
Integra LifeSciences Announces Key Executive Leadership Appointments
Integra LifeSciences has appointed Teshtar Elavia as Chief Technology Officer, Michael Hutchinson as Chief Legal Officer, and Kerri DiPietro as Chief Quality Officer. These seasoned executives bring extensive experience in MedTech innovation, legal affairs, and quality management. The creation of the CTO role highlights Integra's commitment to advancing R&D and fostering long-term growth.
02-17 13:30
Integra LifeSciences Holdings Corporation hat eine Aktualisierung ihres Finanzkalenders veröffentlicht
Integra LifeSciences Holdings Corporation hat eine Aktualisierung ihres Finanzkalenders veröffentlicht Integra LifeSciences Holdings Corporation wird am 26. Februar 2026 vor Börsenbeginn die Finanzzahlen für das vierte Quartal und das Gesamtjahr 2025 veröffentlichen. Die Ergebnisse werden im Bereich
02-09 19:35
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
Integra LifeSciences Holdings Corporation will release its fourth-quarter and full-year 2025 financial results on February 26, 2026, followed by a conference call at 8:30 a.m. ET. A live webcast and registration details are available on the Investors section of the company’s website. Integra, a global medical technology leader, focuses on improving patient outcomes through innovative solutions in neurosurgery and tissue reconstruction.
02-09 11:35
